Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

This study is testing whether giving a seizure prevention medication (levetiracetam) to patients who have brain metastases (cancer that has spread to the brain) located in the motor cortex (the part of the brain that controls movement) can reduce their risk of having a seizure. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a solid cancer that has spread to the brain, with at least one tumor located in the primary motor cortex (0.5 cm or larger) - You have never had a seizure before - Your overall health is adequate (Karnofsky score of 60 or higher) - Your estimated survival is at least 3–6 months **You may NOT be eligible if...** - You have had seizures in the past - You are allergic to levetiracetam - You are already taking a seizure medication for another reason at a significant dose - You have a condition that prevents you from giving informed consent Talk to your doctor to see if this trial is right for you.